Opaleye Management Inc. Buys BridgeBio Pharma Inc, Autolus Therapeutics PLC, Gemini Therapeutics Inc, Sells , ChemoCentryx Inc, TG Therapeutics Inc

• New Purchases: BBIO, AUTL, GMTX, KROS, CKPT, PRQR, IMVT, CRNX, CAPA, ALPN, ARPO, AYLA, LPTX,
• Added Positions: MGNX, AVEO, CBIO, CMRX, KNSA, OPTN, SRRA, LUMO, PTGX, ADMS, MGTA, STRO, PCVX, APTO,
• Reduced Positions: CRDF, BHVN, MYOV, AFIB, STXS, NLTX, EDAP, MCRB, CFRX, XOMA,
• Sold Out: EIDX, CCXI, TGTX, KALV, INFI, TCDA, FPRX, MRUS, PRAX, RYTM, CNCE, AMRN, FULC, AKUS, CATB,

For the details of Opaleye Management Inc.'s stock buys and sells, go to https://www.gurufocus.com/guru/opaleye+management+inc./current-portfolio/portfolio

1. Ocular Therapeutix Inc (OCUL) - 6,480,000 shares, 15.80% of the total portfolio. Shares reduced by 0.46%
2. Chimerix Inc (CMRX) - 4,490,000 shares, 6.43% of the total portfolio. Shares added by 13.48%
3. Protara Therapeutics Inc (TARA) - 2,558,472 shares, 5.99% of the total portfolio.
4. BridgeBio Pharma Inc (BBIO) - 583,767 shares, 5.34% of the total portfolio. New Position
5. Codexis Inc (CDXS) - 1,400,000 shares, 4.76% of the total portfolio.

Opaleye Management Inc. initiated holding in BridgeBio Pharma Inc. The purchase prices were between $55.47 and $72.35, with an estimated average price of $65.45. The stock is now traded at around $61.330000. The impact to a portfolio due to this purchase was 5.34%. The holding were 583,767 shares as of 2021-03-31.

Opaleye Management Inc. initiated holding in Autolus Therapeutics PLC. The purchase prices were between $5.49 and $9.36, with an estimated average price of $7.4. The stock is now traded at around $7.570000. The impact to a portfolio due to this purchase was 1.8%. The holding were 2,112,918 shares as of 2021-03-31.

Opaleye Management Inc. initiated holding in Gemini Therapeutics Inc. The purchase prices were between $12.1 and $18, with an estimated average price of $14.81. The stock is now traded at around $10.830000. The impact to a portfolio due to this purchase was 1.63%. The holding were 810,500 shares as of 2021-03-31.

Opaleye Management Inc. initiated holding in Keros Therapeutics Inc. The purchase prices were between $54 and $75.28, with an estimated average price of $63.3. The stock is now traded at around $53.780000. The impact to a portfolio due to this purchase was 1.44%. The holding were 157,500 shares as of 2021-03-31.

Opaleye Management Inc. initiated holding in Checkpoint Therapeutics Inc. The purchase prices were between $2.6 and $4.16, with an estimated average price of $3.36. The stock is now traded at around $2.680000. The impact to a portfolio due to this purchase was 1.37%. The holding were 2,925,963 shares as of 2021-03-31.

Opaleye Management Inc. initiated holding in ProQR Therapeutics NV. The purchase prices were between $4.14 and $9.22, with an estimated average price of $5.11. The stock is now traded at around $7.590000. The impact to a portfolio due to this purchase was 1.28%. The holding were 1,303,000 shares as of 2021-03-31.

Opaleye Management Inc. added to a holding in Macrogenics Inc by 79.76%. The purchase prices were between $18.99 and $33.2, with an estimated average price of $24.22. The stock is now traded at around $21.890000. The impact to a portfolio due to this purchase was 1.4%. The holding were 666,200 shares as of 2021-03-31.

Opaleye Management Inc. added to a holding in AVEO Pharmaceuticals Inc by 1320.07%. The purchase prices were between $5.97 and $15.28, with an estimated average price of $8.63. The stock is now traded at around $7.040000. The impact to a portfolio due to this purchase was 0.85%. The holding were 835,000 shares as of 2021-03-31.

Opaleye Management Inc. added to a holding in Catalyst Biosciences Inc by 740.05%. The purchase prices were between $4.93 and $7.15, with an estimated average price of $6.1. The stock is now traded at around $4.330000. The impact to a portfolio due to this purchase was 0.83%. The holding were 1,250,000 shares as of 2021-03-31.

Opaleye Management Inc. added to a holding in Kiniksa Pharmaceuticals Ltd by 43.21%. The purchase prices were between $16.68 and $23.97, with an estimated average price of $20.45. The stock is now traded at around $15.020000. The impact to a portfolio due to this purchase was 0.27%. The holding were 320,926 shares as of 2021-03-31.

Opaleye Management Inc. added to a holding in OptiNose Inc by 89.89%. The purchase prices were between $3.47 and $4.75, with an estimated average price of $4.06. The stock is now traded at around $3.620000. The impact to a portfolio due to this purchase was 0.21%. The holding were 826,000 shares as of 2021-03-31.

Opaleye Management Inc. added to a holding in Sierra Oncology Inc by 100.51%. The purchase prices were between $13.94 and $20.33, with an estimated average price of $15.82. The stock is now traded at around $18.250000. The impact to a portfolio due to this purchase was 0.2%. The holding were 151,139 shares as of 2021-03-31.

Opaleye Management Inc. sold out a holding in . The sale prices were between $117.32 and $128.51, with an estimated average price of $123.33.

Opaleye Management Inc. sold out a holding in ChemoCentryx Inc. The sale prices were between $49.53 and $68.4, with an estimated average price of $60.19.

Opaleye Management Inc. sold out a holding in TG Therapeutics Inc. The sale prices were between $41.61 and $54.3, with an estimated average price of $48.04.

Opaleye Management Inc. sold out a holding in KalVista Pharmaceuticals Inc. The sale prices were between $14.69 and $42.57, with an estimated average price of $26.54.

Opaleye Management Inc. sold out a holding in Infinity Pharmaceuticals Inc. The sale prices were between $1.98 and $5.36, with an estimated average price of $3.35.

Opaleye Management Inc. sold out a holding in Tricida Inc. The sale prices were between $4.52 and $7.8, with an estimated average price of $6.29.

Opaleye Management Inc. reduced to a holding in Cardiff Oncology Inc by 65.35%. The sale prices were between $9.1 and $19.57, with an estimated average price of $12.16. The stock is now traded at around $8.000000. The impact to a portfolio due to this sale was -2.58%. Opaleye Management Inc. still held 576,000 shares as of 2021-03-31.

Opaleye Management Inc. reduced to a holding in Biohaven Pharmaceutical Holding Co Ltd by 78.07%. The sale prices were between $64.07 and $91.75, with an estimated average price of $80.92. The stock is now traded at around $94.990000. The impact to a portfolio due to this sale was -1.01%. Opaleye Management Inc. still held 25,000 shares as of 2021-03-31.